Zymeworks, GSK Sign Antibody Deal For Up To $440m
This article was originally published in Scrip
Executive Summary
Zymeworks Inc. nabbed its fourth major partner by entering into a collaboration and licensing deal with GlaxoSmithKline PLC for the development of novel Fc-engineered monoclonal and bi-specific antibodies for the treatment of various undisclosed diseases.